SPOTLIGHT -
Research Explores Connection Between Bacteria and Depression, Anxiety
The results suggest that the bacterium Lactobacillus may aid in the management of stress and in the prevention of these disorders.
From the Pages of Psychiatric Times: November 2023
The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.
Psychiatry in the News: November 2023
Here are some updates from the world of psychiatry throughout the month of November.
FDA Accepts NDA, Grants PDUFA Date for Investigational Schizophrenia Treatment
The FDA’s decision is set for September 2024.
The Week in Review: November 20-24
From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.
Anxiety Research Roundup: November 24, 2023
What is new in research on anxiety symptoms and disorders?
Celebrating Thanksgiving 2023
Psychiatric Times revisits some meaningful reflections on Thanksgiving, family traditions, and the value of gratitude and thankfulness.
The Week in Review: November 13-17
From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.
Psychedelics Research Roundup: November 17, 2023
What is new in research on psychedelics?
The Week in Review: November 6-10
From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.
Dementia Research Roundup: November 10, 2023
What is new in research on dementia?
Study Finds That Long-Acting Schizophrenia Treatment Prolongs Time to Impending Relapse
These results were instrumental in securing the FDA approval of the drug for the treatment of schizophrenia in adults in April 2023.
The Week in Review: October 30-November 3
From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.
Substance Use Disorders Research Roundup: November 3, 2023
What is new in research on SUDs?
What Scares Mental Health Clinicians?
Happy Halloween! To celebrate, Psychiatric Times® is looking back at our Scariest in Psychiatry series, which highlights clinicians’ most frightening, worrisome, and concerning issues in psychiatry.
Positive Topline Results Reported for Phase 3 Clinical Trial Evaluating Schizophrenia Treatment
The trial’s results showed statistically significant reductions in all major symptom domains and secondary endpoints.
From the Pages of Psychiatric Times: October 2023
The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.
The Week in Review: October 23-27
From deep brain stimulation for treatment-resistant schizophrenia to a look at the potential trajectory of artificial intelligence in psychiatry and medicine, here are highlights from the week in Psychiatric Times.
Psychiatry in the News: October 2023
Here are some updates from the world of psychiatry throughout the month of October.
TMS Research Roundup: October 28
What is new in research on TMS?
Understanding Alcohol Misuse in Women
“Epidemiological surveys have shown that gender gaps and alcohol consumption and alcohol-related harms are narrowing for women and men—such that alcohol is growing women’s health issue.”
Getting Started With Buprenorphine
An expert addresses some common concerns about the drug and some effective ways clinicians can initiate the treatment at the 2023 Annual Psychiatric Times™ World CME Conference.
The Week in Review: October 16-20
From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.
Schizophrenia Research Roundup: October 20
What is new in research on schizophrenia?
A Practical Guide to Eliciting Positive Change in Patients Through Motivational Interviewing
An expert discusses motivational interviewing at the 2023 Annual Psychiatric Times™ World CME Conference.
Study Shows 40% of Patients With TRS No Longer Meet Severity Criteria Following Treatment With NCE
The NCE’s developer has announced that it is now initiating phase 3 studies.
Study Finds Connection Between Olanzapine/Samidorphan and Reduced Health Care Utilization in Patients With Schizophrenia, Bipolar I
This study is the first to assess the efficacy of this drug combination in a real-world setting.
The Week in Review: October 2-6
From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.
Depression Research Roundup: October 6
What is new in research on depression?
Study Finds Esketamine Nasal Spray More Likely to Induce Remission in Treatment-Resistant MDD Than Quetiapine Extended Release
“Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray.”